Alamar Biosciences has crossed from a launch-stage proteomics instrument vendor into a consumables-anchored growth platform, with second-quarter fiscal 2026 revenue of $29.4 million printing 82% above the prior-year quarter and full-year guidance lifted to $116 million to $120 million at the midpoint implying 59% growth for 2026. Consumables revenue, the line that defines whether an installed-base play is real or aspirational, grew 147% to $15.5 million in the second quarter, more than double the instrument line's 35% advance. The consumables acceleration matters because it converts the 100-plus ARGO HT instruments placed since the commercial launch in January 2024 into recurring annuity, and a 60% gross margin in the quarter, up from 53% a year ago, is the proof that the recurring model is scaling, not just headline revenue.
The thesis is that Alamar is at a J-curve inflection. The April 2026 initial public offering raised $197.8 million in net proceeds and an immediate $250.1 million cash pile gives the company a four-year operating runway at the first-half 2026 burn rate, with the equity priced at roughly 17.7 times forward sales rather than a multiple of earnings, a fair reflection of a company that loses money on a GAAP basis. The single load-bearing risk is that the third and fourth quarters of 2026 must absorb the order pattern dictated by the academic grant cycle, in which end-of-year grant spending produces a fourth-quarter bump, and any slippage in consumables pull-through or instrument placement would compress the multiple ahead of profitability. The next data point that tests this is the third-quarter print, expected in early November 2026, which is the first quarter where the new eMTBR-tau and Immune 340 panel launches, both announced in the second quarter, contribute a full quarter of revenue.